GlassScriptPhysician profile
Anthony F Dimarco
NPI 1730164740
$8,112.48
in general payments reported to CMS, 2019-2025
25 companies · $129 in 2025
The $129 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,679 · 2020: $1,686 · 2021: $2,247 · 2022: $1,612 · 2023: $735 · 2024: $24.12 · 2025: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $888.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $888.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,927.96 | 2019-2023 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,600.01 | 2019-2025 | Airsupra, Breztri, Symbicort |
| Jazz Pharmaceuticals INC. | $899.95 | 2019-2023 | Xywav |
| Grifols USA, LLC | $530.96 | 2019-2023 | Prolastin-C Liquid |
| Harmony Biosciences LLC | $478.20 | 2020-2023 | Wakix |
| Inspire Medical Systems, INC. | $466.03 | 2019-2023 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $377.47 | 2019-2022 | |
| Genzyme Corporation | $363.16 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $316.81 | 2019-2023 | Opsumit |
| United Therapeutics Corporation | $287.02 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $149.52 | 2019-2020 | |
| Mylan Specialty L.P. | $142.40 | 2019-2023 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $99.89 | 2021-2022 | |
| Axsome Therapeutics, INC. | $91.03 | 2022-2023 | Sunosi |
| Amgen INC. | $78.02 | 2021-2023 | Tezspire |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $71.22 | 2020-2022 | |
| Eisai INC. | $58.23 | 2020-2021 | |
| Genentech USA, INC. | $41.25 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $29.21 | 2022 | |
| Abbott Laboratories | $24.12 | 2024 | Freestyle Libre 3 |
| Fisher & Paykel Healthcare INC | $20.77 | 2019 | |
| Nabriva Therapeutics, Plc | $16.69 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.81 | 2019 | |
| Baxter Healthcare | $13.40 | 2023 | Hillrom - Life 2000 Ventilation System |
| Itamar Medical INC | $13.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Dimarco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.